24 August 2020 

The US Food and Drug Administration (FDA) has granted an emergency use authorisation (EUA) for the use of investigational convalescent plasma to treat Covid-19 in hospitalised patients. The EUA allows the distribution of Covid-19 convalescent plasma in the country and its administration by health care providers.

China-based Sinopharm has commenced a Phase III clinical trial of its Covid-19 vaccine candidate at the Bahrain International Exhibition and Convention Centre. The study involves up to 6,000 volunteers aged more than 18 years. Sinopharm has also obtained approvals to test its potential Covid-19 vaccine in UAE, Argentina, Peru and Morocco, reported Reuters.

India-based Bharat Biotech has obtained the Central Drugs Standard Control Organisation (CDSCO) approval to perform a clinical trial of its Covid-19 vaccine candidate ‘Covaxin’ through intradermal administration. The vaccine is currently being assessed for intramuscular administration.

China has awarded emergency authorisation for Covid-19 vaccine candidates developed by certain domestic companies, according to local media reports. A Chinese health official said that the government has come up with plan packages, including medical consent forms and side-effects monitoring plans, to regulate and monitor the emergency usage.

The University of Sharjah in UAE has signed a research agreement with social initiative Sandooq Al Watan to develop a drug against Covid-19 infection. Part of Sandooq Al Watan’s applied research and development programme, the research focuses on designing a dual-inhibitor antiviral drug to treat the disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.